Adcomm says Intercept’s rare liver disease drug should not get full approval

An FDA ad­vi­so­ry com­mit­tee rec­om­mend­ed against full ap­proval for Al­fasig­ma and In­ter­cept Phar­ma­ceu­ti­cals’ rare liv­er dis­ease drug Ocali­va by a 13-1 vote, con­clud­ing that con­fir­ma­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.